Sunghee Yun (He/Him)

Co-Founder & CTO @ Erudio Bio, Inc., Co-Founder & CEO @ Erudio Bio Korea, Inc., Leader of Silicon Valley Privacy Preserving AI Forum (K-PAI), Director of AI Semiconductor @ K-BioX, AI-Korean Medicine Integration Initiative Task Force Member @ The Association of Korean Medicine, KFAS-Salzburg Global Leadership Initiative Fellow @ Salzburg Global Seminar, Visiting Professor @ Sogang University, Advisory Professor @ DGIST, Global Advisory Board Member @ Innovative Future Brain-Inspired Intelligence System Semiconductor of Sogang University, Network Expert @ Gerson Lehrman Group, Chief Business Development Officer @ WeStory.ai, and Advisor @ CryptoLab, Inc.

posted: 11-Dec-2025 & updated: 11-Dec-2025

subtitle: Building the Future of Life-Long Health Asset Management

Prepared by: Sunghee Yun | Chanik Park | Don Kim

Executive Summary

We are establishing a Medical AI & Biotech Innovation Consortium to launch multiple high-impact initiatives targeting the Life-Long Health Asset Management market—a multi-billion dollar opportunity emerging from the convergence of AI breakthroughs, aging populations, and the fundamental human need to maintain health throughout extended lifespans.

Rather than pursuing a single focused project, we are building a portfolio of synergistic initiatives spanning AI platform development, clinical applications, drug discovery, and health optimization services. This diversified approach:

  • De-risks the venture through multiple paths to market
  • Accelerates learning across complementary domains
  • Maximizes our team’s diverse capabilities
  • Positions us to lead multiple aspects of the medical AI revolution

The consortium uniquely leverages our team’s combination of AI expertise, medical partnerships, industrial execution capability, and strategic networks spanning Silicon Valley, Korea, and global healthcare ecosystems.

I. The Opportunity — Why Now, Why Us

The Durable Market Truth

Humans have evolved to live 30-40 years, yet now routinely live 80+ years. This evolutionary mismatch creates permanent demand for solutions that optimize health throughout lifespans our biology was never designed to support. Unlike temporary market trends, this need is:

  • Universal — every aging human faces this challenge
  • Inevitable — cannot be solved through willpower or lifestyle alone
  • Urgent — global populations aging rapidly
  • Permanent — will persist as long as humans outlive their evolutionary design

The AI Inflection Point

For the first time, AI capabilities match biological complexity:

  • AlphaFold 3 earning the 2024 Nobel Prize validates AI’s transformation of life sciences
  • Multi-modal foundation models can now integrate genomic, proteomic, imaging, and clinical data
  • Agentic AI systems can coordinate complex research and clinical protocols
  • Privacy-preserving AI (homomorphic encryption) enables secure medical data utilization

Why Our Team Can Execute This

Our team represents a rare convergence of capabilities:

Sunghee Yun — world-class AI architect with proven track record

  • PhD from Stanford under Prof. Stephen Boyd (Erdős number 3, mathematical genealogy to Carl Friedrich Gauss)
  • Led Optimization & Industrial AI at Samsung (12 years, tools still used by hundreds of engineers)
  • Senior Applied Scientist at Amazon: led Mobile Shopping App Main Menu Personalization Project (2019) delivering $200M+ revenue increase
  • Co-Founder & CTO/CEO of Erudio Bio (Gates Foundation-backed AI biotech)
  • Leader of K-PAI (Silicon Valley Privacy-Preserving AI Forum)
  • Extensive academic network: delivered 70+ AI seminars at leading universities
  • Deep theoretical foundation in Convex Optimization & the mathematical insight for modern AI (e.g., LLM & genAI)

Chanik Park — execution power and customer relationships

  • CCO at MangoBoost with direct experience commercializing cutting-edge technology
  • Former VP at Samsung Electronics with extensive enterprise sales experience
  • Deep understanding of technology adoption cycles in large organizations
  • Proven ability to translate technical capability into business value

Don Kim — US-Korea network bridge

  • HR Head at SK hynix America, one of the world’s largest semiconductor companies
  • Direct access to Silicon Valley talent pools and investment communities
  • Deep relationships across major Korean conglomerates
  • Experience navigating both Korean and American business cultures
  • Strategic HR expertise critical for building world-class research, technology, and investment organizations

This combination—AI depth, network reach, and execution capability—is exceptionally rare.

II. Strategic Vision — Life-Long Health Asset Management

The Paradigm Shift

Current healthcare is reactive: treat diseases after they appear. The future is proactive health asset management, analogous to financial planning but for the body’s most valuable asset.

Just as people plan finances from their 20s for retirement at 65, they should optimize health from youth for vitality at 80+. This requires a comprehensive ecosystem of technologies, services, and partnerships—not a single product.

The Portfolio Approach — Multiple Synergistic Initiatives

Rather than betting on a single approach, we are pursuing 5 parallel initiatives that address different aspects of the health asset management opportunity:

Initiative 1 — Medical AI Foundation Model Platform

Technology Infrastructure

  • Multi-modal AI model integrating genomic, proteomic, imaging, clinical, and lifestyle data
  • Core platform that powers other initiatives
  • Licensing/API revenue model

Initiative 2 — AI-Powered Clinical Decision Support Systems

B2B Healthcare

  • Deployable tools for hospitals and clinics
  • Disease-specific applications (oncology, cardiology, neurology)
  • Immediate clinical utility and revenue

Initiative 3 — AI-Accelerated Drug Discovery & Biomarker Platform

Pharma Partnerships

  • Novel therapeutic target identification
  • Biomarker discovery for early disease detection
  • Clinical trial optimization
  • Partnership revenue + royalties

Initiative 4 — Personal Health Optimization Service

B2C Consumer

  • Continuous health monitoring and personalized recommendations
  • Integration with wearables and home diagnostics
  • Subscription-based premium wellness service

Initiative 5 — Medical AI Research Consortium

Ecosystem Building

  • Regular expert gatherings (AI researchers, clinicians, data scientists, industry leaders)
  • Government engagement and policy influence
  • Talent pipeline and thought leadership

Synergies Across Initiatives

Each initiative has independent value but creates powerful synergies:

  • Foundation model (Initiative 1) powers clinical tools (Initiative 2) and drug discovery (Initiative 3)
  • Clinical partnerships (Initiative 2) provide data for foundation model (Initiative 1)
  • Consumer service (Initiative 4) provides real-world validation and additional data
  • Research consortium (Initiative 5) attracts talent and funding for all initiatives

This portfolio approach de-risks the overall venture while maximizing optionality and accelerating progress through cross-learning.

III. Strategic Approach

Initiative Focus Areas

Medical AI Foundation Model Platform

Objective: Build a comprehensive multi-modal medical AI foundation model

Technical Approach:

  • Integrate genomic, proteomic, imaging, clinical, and lifestyle data
  • Leverage privacy-preserving AI (homomorphic encryption) for secure data sharing
  • Create API/licensing platform for third-party developers
  • Focus on population-specific optimization advantages

AI-Powered Clinical Decision Support

Objective: Deploy immediately useful AI tools to hospitals for high-impact clinical scenarios

Focus Areas:

  • Early cancer detection from imaging and biomarker patterns
  • Cardiovascular risk prediction and prevention
  • Drug response prediction and treatment optimization
  • Rare disease diagnosis through pattern recognition

AI-Accelerated Drug Discovery

Objective: Partner with pharmaceutical companies to accelerate development

Service Offerings:

  • Target identification and lead optimization
  • Biomarker discovery for early disease detection
  • Clinical trial design and patient stratification
  • Drug repurposing analysis

Personal Health Optimization

Objective: Create premium service for proactive health management

Service Components:

  • Comprehensive health assessment (genetic testing, biomarkers, imaging, lifestyle)
  • AI-powered personalized insights and predictions
  • Actionable recommendations and continuous monitoring
  • Expert consultations and community support

Medical AI Research Consortium

Objective: Establish thought leadership and ecosystem

Activities:

  • Regular expert forums and annual conferences
  • Policy engagement and regulatory influence
  • Academic partnerships and talent programs
  • Strategic industry collaborations

IV. Competitive Advantages

Why We Will Win

Portfolio Synergies

Each initiative feeds the others, creating network effects that no single-focus competitor can match.

Unique Data Advantages

  • Population-specific modeling advantages
  • Privacy-preserving AI enables secure data sharing
  • Multi-initiative approach generates diverse proprietary datasets

Clinical Integration Depth

  • Deep partnerships with leading medical institutions
  • Medical professionals as advisors prevent common AI healthcare failures
  • Multiple clinical use cases provide faster learning cycles

Technical Excellence

  • World-class AI team with proven track record
  • Access to latest Silicon Valley AI developments through K-PAI network
  • Mathematical rigor ensures robust, reliable models
  • Execution capability across diverse technical domains

Strategic Positioning

  • Aligned with national AI and healthcare priorities
  • First-mover advantage across multiple medical AI domains
  • Ecosystem-building creates moat through network effects

V. Vision & Impact

Beyond Business — A Vision for Human Flourishing

While this plan involves significant business opportunities, the ultimate goal transcends commercial success. We are building solutions to one of humanity’s most important challenges: how to live healthily throughout lifespans our biology was never designed to support.

Success means:

  • Parents watching their grandchildren grow up with full cognitive vitality
  • Diseases detected years before symptoms, when they’re most treatable
  • Personalized health strategies that work for each individual’s unique biology
  • Medical innovations improving lives globally

This is the optimization problem worth solving—not just maximizing lifespan, but optimizing for human flourishing in all its dimensions.

Why This Team, Why Now

Our founding team uniquely combines:

  • World-class AI expertise with proven track record across leading technology companies
  • Unmatched international networks providing access to talent, capital, and partnerships
  • Execution capability demonstrated through successful technology commercialization
  • Strategic timing aligned with AI breakthroughs and demographic imperatives

This combination—AI depth, network reach, execution power, and strategic positioning—is exceptionally rare globally.

The Path Forward

The convergence of AI breakthroughs, aging populations, and healthcare transformation creates a once-in-a-generation opportunity. Our multi-initiative portfolio approach provides multiple paths to success while creating synergies that no single-focus competitor can match.

Each initiative has independent value. Together, they create an unassailable competitive moat.

We are building not just a company, but an entire ecosystem that will transform how humanity approaches health and longevity in the 21st century.

VI. Engagement Opportunities

We welcome engagement from:

  • Strategic Partners — Healthcare systems, pharmaceutical companies, and research institutions interested in collaboration
  • Advisors & Experts — Thought leaders in AI, medicine, biotechnology, and healthcare policy
  • Investors — Strategic and financial partners who share our long-term vision
  • Talent — World-class researchers, engineers, clinicians, and business leaders

For more information or to explore partnership opportunities, please contact:

Sunghee Yun
sunghee.yun@gmail.com
https://sungheeyun.github.io

This document represents a strategic overview of our multi-initiative portfolio. Additional details available upon request for qualified partners. We welcome your feedback and look forward to discussing how we can work together to achieve this vision.